MedTech Global Insights

Last week, the US FDA released a bombshell draft guidance for AI/ML-enabled medical devices. This isn't just another update; it's a fundamental shift towards a total lifecycle regulatory model. This new framework, centered on Predetermined Change Control Plans, creates immense challenges but also opportunities for agile innovation. We break down what this means for manufacturers, from startups to...

The U.S. FDA has just sent shockwaves through the diagnostics industry with a final rule to regulate Laboratory Developed Tests (LDTs) as medical devices. This decision eliminates decades of regulatory ambiguity and forces thousands of clinical laboratories into a new world of compliance, including premarket approval and quality system requirements. This episode of MedTech Global Insights breaks d...

The start of 2026 has been marked by a huge wave of multi-billion dollar mergers and acquisitions in the MedTech industry. Giants like Abbott and Boston Scientific are spending big to acquire innovators in diagnostics and neurovascular tech, fundamentally reshaping the competitive landscape. This activity signals a major strategic shift towards portfolio optimization and acquiring innovation rathe...

The FDA has drawn a new line in the sand for medical device cybersecurity. Since March 2024, the "Refuse to Accept" policy is in full effect, turning premarket submissions into a high-risk gamble for unprepared manufacturers. In this episode, we dissect the immediate fallout and what companies are experiencing right now. We explore how a missing Software Bill of Materials (SBOM) or a weak post-mar...

The European Commission has just released critical new guidance on how the EU AI Act and the Medical Device Regulation (MDR) will work together. This creates a new reality of dual regulation for MedTech innovators, fundamentally changing the requirements for placing and maintaining AI-driven medical devices on the European market. This episode breaks down what this new intersection means for manuf...

This week on MedTech Global Insights, we dissect a major strategic win in the cardiovascular space. Abbott's recent dual-market approval for its AI-powered imaging software in both the U.S. and Europe is more than just a headline—it's a blueprint for successful global regulatory strategy. We explore how they navigated two of the world's most difficult regulatory systems at the same time. This epis...

The US FDA's 510(k) pathway has fundamentally changed in 2026. What was once a straightforward process for many devices has now evolved with complex new requirements for cybersecurity and the use of Real-World Evidence. This episode breaks down the critical updates that are reshaping market access strategies and causing unexpected delays for unprepared companies. We explore the practical impact of...

The U.S. FDA has just released transformative new guidance on medical device cybersecurity, moving it from a final-stage checklist to a core requirement throughout the entire product lifecycle. This shift demands a radical new approach, integrating a Secure Product Development Framework (SPDF) from the earliest design stages and extending into post-market surveillance. This change introduces signi...

In this episode, we dissect the groundbreaking new program from the FDA and CMS that bridges the gap between regulatory approval and Medicare reimbursement in the United. States. This policy shift is set to eliminate the "reimbursement valley of death" for the most innovative medical technologies. Imagine your breakthrough AI diagnostic for Alzheimer's just won FDA approval. The celebration is sho...

This week, MedTech Global Insights tackles the monumental shift in the U.S. regulatory landscape: the new Quality Management System Regulation (QMSR). While the FDA’s alignment with ISO 13485 promises global harmony, we uncover the hidden complexities and critical differences that many manufacturers are overlooking. We dive into why your ISO 13485 certificate is not a golden ticket and discuss the...

This week, we dive into the groundbreaking joint guidance on AI/ML medical devices recently released by US and EU regulators. This new framework for Predetermined Change Control Plans (PCCPs) promises to accelerate innovation by allowing pre-approved software updates. It's a game-changer for any company operating in the AI MedTech space. But beneath this promising development lies a complex web of...

Last week, the US FDA and CMS announced the TCET pathway, a landmark program to accelerate insurance coverage for innovative medical devices. This move aims to eliminate the notorious "valley of death" where approved devices fail to secure reimbursement, but it also creates new strategic challenges for MedTech manufacturers. This episode of MedTech Global Insights dives into the specifics of this...

This week, we dissect the major regulatory shift in Singapore, as the Health Sciences Authority (HSA) releases groundbreaking new guidance for AI and Machine Learning medical devices. This move tightens the rules on "continuous learning" algorithms and sets a potential new global standard for the industry. This update places a heavy new burden on manufacturers, requiring detailed pre-planned modif...

Last week, the European MedTech landscape was thrown into chaos. A major Notified Body was suddenly delisted, leaving hundreds of device manufacturers with invalid CE marks and effectively halting their market access overnight. This episode of MedTech Global Insights dissects the fallout from this regulatory earthquake. We explore the immediate operational and financial panic this creates for comp...

In this episode, we dissect the FDA's monumental decision to regulate Laboratory Developed Tests (LDTs) as medical devices, ending a long-standing policy of enforcement discretion. We explore what this regulatory shift means for the diagnostics industry, from small hospital labs to large commercial players. This change introduces significant new hurdles for labs that have historically developed an...

This episode of MedTech Global Insights unpacks the massive $13.1 billion acquisition of Shockwave Medical by Johnson & Johnson. We explore the groundbreaking sound-wave technology that made Shockwave a prime target and analyze what this deal reveals about the "buy vs. build" strategy dominating the cardiovascular device market. Imagine your innovative medical device is finally gaining traction. S...

This week, MedTech Global Insights dives into the sudden regulatory shift from the UK's MHRA, which has enforced a new, stricter framework for AI medical devices. This unexpected announcement creates significant hurdles for global manufacturers, particularly those relying on EU or US data for their product validation. We explore how this divergence from EU regulations impacts market access and wha...

This week on MedTech Global Insights, we dissect the major announcement of a new regulatory alignment between the UK's MHRA and the US FDA. This move could potentially reshape market access strategies for medical device manufacturers, offering a streamlined path to two of the world's largest markets. We go beyond the headlines to explore the practical implications, hidden challenges, and strategic...

This week, we dive into the most significant shift in U.S. MedTech regulations in years: the FDA's new Quality Management System Regulation (QMSR). While it harmonizes with the global ISO 13485 standard, manufacturers who assume their existing certification is a free pass for U.S. market compliance are in for a rude awakening. This episode exposes the critical gaps between ISO 13485 and the final...

This week, we dissect the groundbreaking FDA approval of a first-of-its-kind device for pancreatic cancer. This new technology, which combines focused ultrasound with AI targeting, offers new hope for patients but also shines a light on the critical challenges that follow a regulatory victory. We explore the often-underestimated 'valley of death' that occurs after a device is approved. For the com...

The wall between MedTech innovation and regulatory compliance is crumbling. A recent surge in regulatory expectations for digital health and AI-powered devices is forcing a radical shift in corporate strategy. What was once a final hurdle before launch is now a critical, C-suite-level decision that must be integrated from the earliest stages of product design. This episode of MedTech Global Insigh...

This week, we dive into a major strategic shift in the MedTech landscape. In early April, regulatory bodies in both Brazil and South Korea made pivotal announcements strengthening their integration of the Medical Device Single Audit Program (MDSAP). This signals a powerful move towards global harmonization, creating unprecedented opportunities for efficient market access. In this episode of MedTec...

A targeted ransomware attack on a German hospital network has exposed critical vulnerabilities in thousands of connected medical devices, triggering an emergency regulatory response from the European Union. This episode of MedTech Global Insights unpacks the incident and the urgent new cybersecurity mandates facing manufacturers. We explore the far-reaching implications of the new 72-hour security...

The regulatory gap for AI-powered medical devices between the United States and Europe is widening into a major challenge for MedTech innovators. What was once a straightforward path—FDA approval followed by a European CE Mark—is now a complex maze of diverging requirements, forcing companies to rethink their entire global strategy from day one. This episode delves into the critical differences be...

This week, we dissect the EU's surprising new cybersecurity guidance for AI medical devices. Released just last week, this new framework moves beyond traditional compliance, demanding that MedTech innovators build dynamic, continuous defenses against sophisticated AI-specific threats like adversarial attacks and model drift. This shift creates immediate, complex challenges for companies that previ...